Header Logo

Connection

JOSEPH JANKOVIC to Movement Disorders

Back to Details
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Movement Disorders.
JOSEPH JANKOVIC
Connection Strength
23.452
Movement Disorders
  1. Peripherally-induced Movement Disorders: An Update. Tremor Other Hyperkinet Mov (N Y). 2023; 13:8.
    View in: PubMed
    Score: 0.661
  2. Sports-Related Dystonia. Tremor Other Hyperkinet Mov (N Y). 2021; 11:54.
    View in: PubMed
    Score: 0.605
  3. Editorial "Parkinsonism across the spectrum of movement disorders and beyond". J Neurol Sci. 2022 Feb 15; 433:120013.
    View in: PubMed
    Score: 0.596
  4. The Clinical Value of Patient Home Videos in Movement Disorders. Tremor Other Hyperkinet Mov (N Y). 2021; 11:37.
    View in: PubMed
    Score: 0.595
  5. Beyond tics: movement disorders in patients with Tourette syndrome. J Neural Transm (Vienna). 2021 08; 128(8):1177-1183.
    View in: PubMed
    Score: 0.588
  6. Botulinum Toxin in Movement Disorders: An Update. Toxins (Basel). 2021 Jan 08; 13(1).
    View in: PubMed
    Score: 0.567
  7. Psychogenic (Functional) Movement Disorders. Continuum (Minneap Minn). 2019 Aug; 25(4):1121-1140.
    View in: PubMed
    Score: 0.513
  8. The Wide Spectrum of Functional Movement Disorders. JAMA Neurol. 2019 02 01; 76(2):235-236.
    View in: PubMed
    Score: 0.496
  9. Autoimmune and paraneoplastic movement disorders: An update. J Neurol Sci. 2018 02 15; 385:175-184.
    View in: PubMed
    Score: 0.460
  10. An update on new and unique uses of botulinum toxin in movement disorders. Toxicon. 2018 Jun 01; 147:84-88.
    View in: PubMed
    Score: 0.450
  11. Botulinum toxin: State of the art. Mov Disord. 2017 Aug; 32(8):1131-1138.
    View in: PubMed
    Score: 0.443
  12. Movement disorders in 2016: Progress in Parkinson disease and other movement disorders. Nat Rev Neurol. 2017 Feb; 13(2):76-78.
    View in: PubMed
    Score: 0.430
  13. Examiner manoeuvres 'sensory tricks' in functional (psychogenic) movement disorders. J Neurol Neurosurg Psychiatry. 2017 05; 88(5):453-455.
    View in: PubMed
    Score: 0.428
  14. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016 Dec; 17(18):2461-2470.
    View in: PubMed
    Score: 0.427
  15. Parkinsonism, movement disorders and genetics in frontotemporal dementia. Nat Rev Neurol. 2016 Mar; 12(3):175-85.
    View in: PubMed
    Score: 0.404
  16. Movement disorders induced by deep brain stimulation. Parkinsonism Relat Disord. 2016 Apr; 25:1-9.
    View in: PubMed
    Score: 0.401
  17. Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions. Mov Disord. 2015 Dec; 30(14):1862-9.
    View in: PubMed
    Score: 0.395
  18. Speech and voice disorders in patients with psychogenic movement disorders. J Neurol. 2015 Nov; 262(11):2420-4.
    View in: PubMed
    Score: 0.388
  19. The therapeutic potential of cannabinoids for movement disorders. Mov Disord. 2015 Mar; 30(3):313-27.
    View in: PubMed
    Score: 0.376
  20. Paroxysmal movement disorders. Neurol Clin. 2015 Feb; 33(1):137-52.
    View in: PubMed
    Score: 0.376
  21. Psychogenic movement disorders. Neurol Clin. 2015 Feb; 33(1):205-24.
    View in: PubMed
    Score: 0.376
  22. Movement disorders. Neurol Clin. 2015 Feb; 33(1):xv-xvi.
    View in: PubMed
    Score: 0.376
  23. Genetic movement disorders in patients of Jewish ancestry. JAMA Neurol. 2014 Dec; 71(12):1567-72.
    View in: PubMed
    Score: 0.371
  24. Movement disorders in catatonia. J Neurol Neurosurg Psychiatry. 2015 Aug; 86(8):825-32.
    View in: PubMed
    Score: 0.370
  25. "Psychogenic" versus "functional" movement disorders? That is the question. Mov Disord. 2014 Nov; 29(13):1697-8.
    View in: PubMed
    Score: 0.367
  26. Parkinson disease subtypes. JAMA Neurol. 2014 Apr; 71(4):499-504.
    View in: PubMed
    Score: 0.354
  27. Editorial: Neurotherapeutics of movement disorders. Neurotherapeutics. 2014 Jan; 11(1):3-5.
    View in: PubMed
    Score: 0.348
  28. Restless legs syndrome and cerebrovascular disease - authors' reply. Lancet Neurol. 2013 Aug; 12(8):734-5.
    View in: PubMed
    Score: 0.339
  29. Movement disorders in cerebrovascular disease. Lancet Neurol. 2013 Jun; 12(6):597-608.
    View in: PubMed
    Score: 0.332
  30. Yips and other movement disorders in golfers. Mov Disord. 2013 May; 28(5):576-81.
    View in: PubMed
    Score: 0.330
  31. Movement disorders in multiple sclerosis and other demyelinating diseases. J Neurol Sci. 2013 May 15; 328(1-2):1-8.
    View in: PubMed
    Score: 0.330
  32. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013 Jun 01; 67:94-114.
    View in: PubMed
    Score: 0.327
  33. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013 Feb; 28(2):210-5.
    View in: PubMed
    Score: 0.325
  34. Current concepts in Parkinson's disease and other movement disorders. Curr Opin Neurol. 2012 Aug; 25(4):429-32.
    View in: PubMed
    Score: 0.316
  35. Movement disorders in autoimmune diseases. Mov Disord. 2012 Jul; 27(8):935-46.
    View in: PubMed
    Score: 0.311
  36. Convergence spasm in conversion disorders: prevalence in psychogenic and other movement disorders compared with controls. J Neurol Neurosurg Psychiatry. 2012 Feb; 83(2):202-4.
    View in: PubMed
    Score: 0.298
  37. Transcutaneous electrical stimulation (TENS) for psychogenic movement disorders. J Neuropsychiatry Clin Neurosci. 2011; 23(2):141-8.
    View in: PubMed
    Score: 0.283
  38. Alcohol in essential tremor and other movement disorders. Mov Disord. 2010 Oct 30; 25(14):2274-84.
    View in: PubMed
    Score: 0.280
  39. Respiratory problems in neurologic movement disorders. Parkinsonism Relat Disord. 2010 Dec; 16(10):628-38.
    View in: PubMed
    Score: 0.275
  40. Education research: patient telephone calls in a movement disorders center: lessons in physician-trainee education. Neurology. 2009 Sep 08; 73(10):e50-2.
    View in: PubMed
    Score: 0.258
  41. Treatment of hyperkinetic movement disorders. Lancet Neurol. 2009 Sep; 8(9):844-56.
    View in: PubMed
    Score: 0.258
  42. Movement disorders. Preface. Neurol Clin. 2009 Aug; 27(3):ix-x.
    View in: PubMed
    Score: 0.257
  43. Peripherally induced movement disorders. Neurol Clin. 2009 Aug; 27(3):821-32, vii.
    View in: PubMed
    Score: 0.257
  44. Movement disorders in musicians. Mov Disord. 2008 Oct 30; 23(14):1957-65.
    View in: PubMed
    Score: 0.243
  45. Psychogenic movement disorders in children. Mov Disord. 2008 Oct 15; 23(13):1875-81.
    View in: PubMed
    Score: 0.243
  46. Parkinson's disease and movement disorders: moving forward. Lancet Neurol. 2008 Jan; 7(1):9-11.
    View in: PubMed
    Score: 0.230
  47. Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. J Neurosurg. 2007 Apr; 106(4):621-5.
    View in: PubMed
    Score: 0.218
  48. Long-term prognosis of patients with psychogenic movement disorders. Parkinsonism Relat Disord. 2006 Sep; 12(6):382-7.
    View in: PubMed
    Score: 0.206
  49. Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol. 2006 Mar; 3(3):138-48.
    View in: PubMed
    Score: 0.202
  50. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother. 2006 Jan; 6(1):7-17.
    View in: PubMed
    Score: 0.200
  51. Real-World Experiences with VMAT2 Inhibitors in Pediatric Hyperkinetic Movement Disorders. Tremor Other Hyperkinet Mov (N Y). 2025; 15:26.
    View in: PubMed
    Score: 0.193
  52. Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms. Chin Med Sci J. 2005 Mar; 20(1):44-7.
    View in: PubMed
    Score: 0.189
  53. Evidence-based review of patient-reported outcomes with botulinum toxin type A. Clin Neuropharmacol. 2004 Sep-Oct; 27(5):234-44.
    View in: PubMed
    Score: 0.182
  54. Current opinions and practices in post-stroke movement disorders: Survey of movement disorders society members. J Neurol Sci. 2024 03 15; 458:122925.
    View in: PubMed
    Score: 0.175
  55. Psychogenic movement disorders: diagnosis and management. CNS Drugs. 2004; 18(7):437-52.
    View in: PubMed
    Score: 0.174
  56. COVID19-associated new-onset movement disorders: a follow-up study. J Neurol. 2023 May; 270(5):2409-2415.
    View in: PubMed
    Score: 0.165
  57. Paroxysmal kinesigenic dyskinesias. Semin Pediatr Neurol. 2003 Mar; 10(1):68-79.
    View in: PubMed
    Score: 0.164
  58. Movement disorders in Friedreich's ataxia. J Neurol Sci. 2003 Jan 15; 206(1):59-64.
    View in: PubMed
    Score: 0.163
  59. Head injury and posttraumatic movement disorders. Neurosurgery. 2002 May; 50(5):927-39; discussion 939-40.
    View in: PubMed
    Score: 0.155
  60. Surgery for Parkinson disease and other movement disorders: benefits and limitations of ablation, stimulation, restoration, and radiation. Arch Neurol. 2001 Dec; 58(12):1970-2.
    View in: PubMed
    Score: 0.151
  61. Worldwide barriers to genetic testing for movement disorders. Eur J Neurol. 2021 06; 28(6):1901-1909.
    View in: PubMed
    Score: 0.144
  62. Can peripheral trauma induce dystonia and other movement disorders? Yes! Mov Disord. 2001 Jan; 16(1):7-12.
    View in: PubMed
    Score: 0.142
  63. Functional gait disorders, clinical phenomenology, and classification. Neurol Sci. 2020 Apr; 41(4):911-915.
    View in: PubMed
    Score: 0.132
  64. Pathogenesis and pathophysiology of functional (psychogenic) movement disorders. Neurobiol Dis. 2019 07; 127:32-44.
    View in: PubMed
    Score: 0.124
  65. Post-traumatic movement disorders: effect of the legal system on outcome. J Forensic Sci. 1998 Mar; 43(2):334-9.
    View in: PubMed
    Score: 0.116
  66. Treatable inherited rare movement disorders. Mov Disord. 2018 01; 33(1):21-35.
    View in: PubMed
    Score: 0.112
  67. ADCY5-related movement disorders: Frequency, disease course and phenotypic variability in a cohort of paediatric patients. Parkinsonism Relat Disord. 2017 Aug; 41:37-43.
    View in: PubMed
    Score: 0.110
  68. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997 Feb; 48(2):358-62.
    View in: PubMed
    Score: 0.108
  69. Thalamic surgery for movement disorders. Adv Neurol. 1997; 74:221-33.
    View in: PubMed
    Score: 0.107
  70. Delayed-onset progressive movement disorders after static brain lesions. Neurology. 1996 Jan; 46(1):68-74.
    View in: PubMed
    Score: 0.100
  71. Movement Disorders From the Use of Metoclopramide and Other Antiemetics in the Treatment of Migraine. Headache. 2016 Jan; 56(1):153-61.
    View in: PubMed
    Score: 0.099
  72. Paroxysmal dyskinesias: clinical features and classification. Ann Neurol. 1995 Oct; 38(4):571-9.
    View in: PubMed
    Score: 0.098
  73. International Classification of Diseases, tenth revision: neurological adaptation (ICD-10 NA): extrapyramidal and movement disorders. Mov Disord. 1995 Sep; 10(5):533-40.
    View in: PubMed
    Score: 0.098
  74. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol. 1995 Jun; 18(3):197-214.
    View in: PubMed
    Score: 0.096
  75. Myorhythmia: phenomenology, etiology, and treatment. Mov Disord. 2015 Feb; 30(2):171-9.
    View in: PubMed
    Score: 0.093
  76. Post-traumatic movement disorders: central and peripheral mechanisms. Neurology. 1994 Nov; 44(11):2006-14.
    View in: PubMed
    Score: 0.092
  77. Botulinum toxin in movement disorders. Curr Opin Neurol. 1994 Aug; 7(4):358-66.
    View in: PubMed
    Score: 0.091
  78. Sensory aspects of movement disorders. Lancet Neurol. 2014 Jan; 13(1):100-12.
    View in: PubMed
    Score: 0.087
  79. Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. J Neural Transm (Vienna). 2013 Nov; 120(11):1579-89.
    View in: PubMed
    Score: 0.083
  80. The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord. 2013 Apr; 28(4):543-7.
    View in: PubMed
    Score: 0.082
  81. Deep brain stimulation hardware complications in patients with movement disorders: risk factors and clinical correlations. Stereotact Funct Neurosurg. 2012; 90(5):300-6.
    View in: PubMed
    Score: 0.079
  82. Iron dysregulation in movement disorders. Neurobiol Dis. 2012 Apr; 46(1):1-18.
    View in: PubMed
    Score: 0.076
  83. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. J Neuroimmunol. 2011 Dec 15; 240-241:121-8.
    View in: PubMed
    Score: 0.075
  84. Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients. J Neuroimmunol. 2011 Aug 15; 237(1-2):66-72.
    View in: PubMed
    Score: 0.073
  85. Cervical dystonia: clinical findings and associated movement disorders. Neurology. 1991 Jul; 41(7):1088-91.
    View in: PubMed
    Score: 0.073
  86. Peripheral trauma and movement disorders: a systematic review of reported cases. J Neurol Neurosurg Psychiatry. 2011 Aug; 82(8):892-8.
    View in: PubMed
    Score: 0.072
  87. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord. 2011 Jan; 26(1):147-52.
    View in: PubMed
    Score: 0.069
  88. Hemiballism-hemichorea. Clinical and pharmacologic findings in 21 patients. Arch Neurol. 1989 Aug; 46(8):862-7.
    View in: PubMed
    Score: 0.064
  89. Lesch-Nyhan syndrome: a study of motor behavior and cerebrospinal fluid neurotransmitters. Ann Neurol. 1988 May; 23(5):466-9.
    View in: PubMed
    Score: 0.059
  90. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology. 1988 Mar; 38(3):391-4.
    View in: PubMed
    Score: 0.058
  91. Cranial-cervical dyskinesias: an overview. Adv Neurol. 1988; 49:1-13.
    View in: PubMed
    Score: 0.057
  92. Motor, behavioral and pharmacologic findings in Tourette's syndrome. Can J Neurol Sci. 1987 Aug; 14(3 Suppl):541-6.
    View in: PubMed
    Score: 0.056
  93. The effect of deep brain stimulation on quality of life in movement disorders. J Neurol Neurosurg Psychiatry. 2005 Sep; 76(9):1188-93.
    View in: PubMed
    Score: 0.049
  94. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004 Jul; 75(7):951-7.
    View in: PubMed
    Score: 0.045
  95. Differential diagnosis and etiology of tics. Adv Neurol. 2001; 85:15-29.
    View in: PubMed
    Score: 0.035
  96. Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. Parkinsonism Relat Disord. 2020 08; 77:141-145.
    View in: PubMed
    Score: 0.034
  97. Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry. 2000 Feb; 68(2):186-90.
    View in: PubMed
    Score: 0.033
  98. Treating severe bruxism with botulinum toxin. J Am Dent Assoc. 2000 Feb; 131(2):211-6.
    View in: PubMed
    Score: 0.033
  99. Outcome after stereotactic thalamotomy for dystonia and hemiballismus. Neurosurgery. 1995 Mar; 36(3):501-7; discussion 507-8.
    View in: PubMed
    Score: 0.024
  100. Essential tremor: clinical correlates in 350 patients. Neurology. 1991 Feb; 41(2 ( Pt 1)):234-8.
    View in: PubMed
    Score: 0.018
  101. Rett syndrome and associated movement disorders. Mov Disord. 1990; 5(3):195-202.
    View in: PubMed
    Score: 0.017
  102. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
    View in: PubMed
    Score: 0.015
  103. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan; 22(1):41-7.
    View in: PubMed
    Score: 0.013
  104. Posteroventral medial pallidotomy for treatment of Parkinson's disease: preoperative magnetic resonance imaging features and clinical outcome. J Neurosurg. 1998 Aug; 89(2):194-9.
    View in: PubMed
    Score: 0.007
  105. Assessment of motor function after stereotactic pallidotomy. Neurology. 1998 Jan; 50(1):266-70.
    View in: PubMed
    Score: 0.007
  106. Extrapyramidal involvement in Rett's syndrome. Neurology. 1990 Feb; 40(2):293-5.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.